Part 3: Myelodysplastic syndromes—treatment of low-risk patients without the 5q deletion (2018)
Fonte: Hematology. Unidade: FM
Assuntos: HEMATOLOGIA, ANEMIA, TRANSFUSÃO DE SANGUE, IMUNOSSUPRESSÃO
ABNT
VELLOSO, Elvira Deolinda Rodrigues Pereira et al. Part 3: Myelodysplastic syndromes—treatment of low-risk patients without the 5q deletion. Hematology, v. 40, n. 3, p. 267-273, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2018.05.011. Acesso em: 27 ago. 2024.APA
Velloso, E. D. R. P., Magalhães, S. M. M., Chauffaille, M. de L. L. F., Buzzini, R., & Bernardo, W. M. (2018). Part 3: Myelodysplastic syndromes—treatment of low-risk patients without the 5q deletion. Hematology, 40( 3), 267-273. doi:10.1016/j.htct.2018.05.011NLM
Velloso EDRP, Magalhães SMM, Chauffaille M de LLF, Buzzini R, Bernardo WM. Part 3: Myelodysplastic syndromes—treatment of low-risk patients without the 5q deletion [Internet]. Hematology. 2018 ; 40( 3): 267-273.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1016/j.htct.2018.05.011Vancouver
Velloso EDRP, Magalhães SMM, Chauffaille M de LLF, Buzzini R, Bernardo WM. Part 3: Myelodysplastic syndromes—treatment of low-risk patients without the 5q deletion [Internet]. Hematology. 2018 ; 40( 3): 267-273.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1016/j.htct.2018.05.011